AI in Pharma
Transforming Sample and Biomarker Data into a Force Amplifier and Decision Accelerator
Tobias Guennel, SVP, Product Innovation/Chief Architect, QuartzBio, part of Precision for Medicine
Drug development teams make data-driven decisions, but these decisions can be limited by disparate data sources, siloed technologies, and fragmented insights. Deploying generative artificial intelligence in drug development can empower users to access and interact with sample and biomarker data in new ways and extract insights at the speed of decisioning.
1. Could you provide insights into how artificial intelligence (AI) is currently being employed to analyse sample and biomarker data in clinical research?
AI is currently being employed in various ways throughout clinical research. Some examples include identification of drug targets, patient recruitment, and synthesisation of information from scientific literature. AI and machine learning algorithms can help researchers sift through vast amounts of clinical trial data before a clinical trial begins, which can help determine the appropriate patient population for their study. One of its applications in clinical trial research and design is the amplification of data management and insight generation to support patient selection strategies, drive clinical trial efficiency and democratise knowledge across scientific teams, which is a focus area of QuartzBio’s AI-powered Biomarker Intelligence Platform to support critical workflows and decisions that must be made throughout the precision medicine lifecycle.
2. How do these AI applications enhance the efficiency and accuracy of sample and biomarker data analysis?
One of the core challenges faced by the life science industry and more specifically by drug development teams is a disconnected data and technology ecosystem, resulting in fragmented insights from sample and biomarker data assets. Instead of spending time on high-value work, teams are left manually navigating between various files or spreadsheets to analyse this critical data. QuartzBio’s AI-enabled Data Management and Business Intelligence tools can address this challenge by streamlining and automating data ingestion, quality control, and standardisation. This process establishes a high-quality data foundation, which subsequently enables insights through conversational and prescriptive AI capabilities. These insights are easily consumable and highlight operational and scientific trends within a sponsor’s data asset.
3. In what ways does AI serve as a force amplifier in transforming sample and biomarker data into actionable insights?
AI serves as a force amplifier in transforming sample and biomarker data into actionable insights in several ways:
Efficient Data Management: By leveraging natural language processing and workflow automation, AI significantly reduces the time spent on lowvalue data management activities, such as locating, organising, processing, and mapping sample and biomarker data. This efficiency allows scientific, operations, and data teams to allocate more time to high-value tasks such as insight generation, biomarker-guided decision-making, and collaboration. Teams are therefore more productive and are able to extract the maximum value out of precious clinical trial samples and data..
Instant Insight Generation: AI dramatically shortens the time from question to answer. Machine learning algorithms, combined with natural language understanding, can quickly sift through vast amounts of data, providing rapid responses to users, even users without specific data expertise. This combination of user accessibility and speed is particularly beneficial for time-sensitive decisions in clinical program management, which can lead to improved patient and business outcomes.
Discovering Hidden Trends: Through pattern recognition and machine learning, AI has the unique ability to uncover trends in sample or biomarker data that were previously hidden or unnoticed. These insights, in the context of a connected ecosystem where biomarker and sample data are linked, can directly inform clinical programs. Example outcomes include using these insights to guide patient / dose selection or identify new therapeutic targets.
4. How does the integration of AI technologies accelerate decisionmaking processes in clinical research?
The integration of AI technologies significantly accelerates decision-making processes in clinical research in several ways:
Shortening the Question-to-Insight Lifecycle: Clinical trials generate millions of data points. AI can process and analyse large volumes of clinical, sample, and biomarker data, rapidly transforming raw information into actionable insights informed by business rules.
Enabling Complex Queries: Generative AI technologies allow for iterative data exploration. This means that, as initial questions are answered, researchers can pivot to more complex or nuanced questions. Extracting more comprehensive, detailed insights in this way empowers teams to make more informed decisions, faster.
Broadening Use Cases: AI technologies operating on interconnected clinical programme data assets allow researchers to explore a broader range of use cases. By linking different data sets, AI can uncover correlations and patterns that might be missed in more traditional, siloed approaches to data analysis.
Augmenting Human Expertise: The most successful applications of AI to clinical research combine AI-enabled processes with human scientific and operational expertise. AI can process data and recognise patterns, but human experts are still needed to provide context, interpret results, and make final decisions. This combination of AI and human life science domain-specific expertise leads to more accurate and effective decision-making in clinical research.
In conclusion, the integration of AI technologies in clinical research not only accelerates decision-making processes but also enhances the depth and breadth of insights obtained, ultimately leading to more effective and efficient research outcomes.
5. What challenges do you encounter in implementing AI for analysing sample and biomarker data, and how do you overcome them?
Implementing AI for analysing sample and biomarker data presents several challenges, but with the right strategies, these can be effectively managed:
Data Privacy and Security: Protecting the privacy and security of clinical, sample and biomarker data is crucial for ethical and regulatory compliance. The risk of data breaches can be mitigated by avoiding the use of third-party APIs, which may have unknown security vulnerabilities. Instead, using trusted and secure hosted-platforms can help ensure that data remains confidential and secure.
Data Quality: The principle of “garbage in, garbage out” is particularly relevant in AI. Poor quality or inaccurate data can lead to misleading or incorrect results. This challenge can be addressed by building a strong foundation of high-quality, consistent sample and biomarker data. This involves rigorous data cleaning, validation, and preprocessing procedures to ensure that the data fed into the AI models is accurate and reliable.
Model Validation: AI models need to be validated to ensure their accuracy and reliability. This can be achieved by implementing a robust validation framework. Incorporating a “Human-in-the-Loop” approach, where human experts review and verify the AI’s outputs, can provide an additional layer of checks and balances. This not only helps in catching errors but also in refining the AI models over time.
6.What opportunities do you foresee in the future for further leveraging AI in this domain?
As the market becomes more saturated with AI-powered products or capabilities with their own domain-specific benefits, it’s going to be important that these technologies can integrate with or work in conjunction with other similar technologies to meet the needs of the market. In this domain, there won’t be one solution that can solve every challenge, so the more user-friendly and interconnective these technologies can be, the easier they will be to implement into existing environments to support specific initiatives.
7. Are there any ethical or regulatory considerations that need to be addressed when utilising AI in sample and biomarker data analysis?
Yes, there are several ethical and regulatory considerations that need to be addressed when utilising AI in sample and biomarker data analysis:
Data Privacy and Security: AI technologies often require access to large volumes of data, which may include sensitive patient information. It’s crucial to ensure that AI frameworks are integrated into secure data workflows that comply with privacy regulations and support secure data storage and processing to prevent unauthorised access.
Regulatory Guidance: Various regulatory agencies have provided guidance on leveraging AI throughout the drug development lifecycle. It’s important to stay updated with these guidelines and ensure that the use of AI aligns with them.
GxP Compliance: While AI can enhance many aspects of clinical research, it’s essential to follow existing processes to support best GxP practices. These practices ensure that the products support their intended use and adhere to quality processes during the Software Development Lifecycle.
Risk-Based Approach: Given the inherent challenges posed by new technologies to existing paradigms, a risk-based approach should be applied to support GxP requirements where needed to ensure data privacy, data security and model performance and accuracy.This involves identifying potential risks associated with the use of AI, assessing their impact, and implementing strategiesto mitigate them.
Human-in-the-Loop Approach: Despite the capabilities of AI, human oversight is still crucial. A human-inthe-loop approach allows for checks and balances, ensuring that the AI system’s outputs are accurate and reliable. This approach combines the strengths of AI with human judgement and expertise.
In conclusion, while AI holds great promise for enhancing clinical research, it’s essential to navigate its use carefully, considering the ethical and regulatory aspects to ensure its benefits are realised responsibly and safely.
8.What do you envision as the future trajectory of AI applications in transforming sample and biomarker data analysis in clinical research?
The future of AI in the domain of sample and biomarker data analysis holds immense potential and opportunities:
Revolutionising Drug R&D: AI is poised to change drug research and development in novel ways, making the process more efficient and effective, which can help automate processes that were once manual and time-consuming and ultimately accelerate R&D workflows.
Optimisation of Learning Capabilities: There is an expected focus on the optimisation of AI’s learning capabilities that empower output and outcomes. This means delivering more value, speed, and accuracy in data analysis and interpretation. This also drives the importance of domainspecific learning capabilities that can continue to learn and adapt in a specialised environment for the most accurate and optimised output.
Evolution of Capabilities and Processes: AI will help capabilities and processes evolve to become more predictive or prescriptive in nature. This evolution will enable more proactive and informed decision-making in the field. Rather than just pointing in the right direction to solve a challenge, AI-enabled technology can flag discrepancies or issues and recommend options or actions to solve them. This feature enhances the problem-solving capacity in the domain and helps users work smarter, not harder.
In conclusion, the future of AI in this domain is promising, with the potential to significantly enhance the efficiency and effectiveness of sample and biomarker data analysis coupled with shortening time-to-insight significantly.
9. How do you see AI continuing to shape the landscape of clinical research in the years to come?
AI is expected to continue shaping the landscape of clinical research by disrupting practices across the R&D lifecycle, impacting clinical and translational research as well as trial planning and management, leading to continual adoption by pharma and biotech innovators and leaders. As adoption of AI throughout clinical research continues to grow,
we expect to see these capabilities lend themselves to key growth areas that can drive the most impact. At QuartzBio, we see the importance of AI to fuel and support precision medicine efforts across the drug development lifecycle and the need for purpose-built technology that can support R&D teams in this work.
10. Any other comments?
AI is not a new concept; it’s been around for a while and has been used to support core research activities, especially around drug target identification, validation, and screening. Recent advances in computational capacity coupled with the emergence of transformer-based AI models have enabled AI to surpass current applications and really broaden its reach and use cases in the drug R&D space.
Author Bio
Tobi has over 12 years of experience leading informatics, data science and software development operations, driving innovation and development of technology solutions across a variety of data-centric spaces ranging from development of complex biomarker signatures for use in patient selection, to deployment of enterprise software solutions geared towards pharmaceutical and biotechnology companies. As SVP of Product Innovation and Chief Architect at QuartzBio, Tobi leads QuartzBio’s Product Innovation organisation while continuing to drive the technology vision for QuartzBio's next phase of development and growth.
